TNFRSF17 and plasma cell myeloma: In particular, PEG (polyethylene glycol)-ylated liposomal nanoparticles encapsulated with DOX and carfilzomib (CFZ)11 or DEX22; BCMA (B-cell maturation antigen)-targeted liposomes 21; and VLA-4 (Very Late Antigen-4, also known as α4β1 integrin) and LPAM-1 (Leukocyte Peyer’s Patch Adhesion Molecule-1, also known as α4β7 integrin) dual-targeted liposomes31 show potent anti-myeloma activity.